Venous thromboembolism (VTE) is known to be a common respiratory and/or cardiovascular complication in hospitalized patients with viral infections. Numerous studies have proven human immunodeficiency virus infection to be a prothrombotic condition. An elevated VTE risk has been observed in critically ill H1N1 influenza patients. VTE risk is remarkably higher in patients infected with the Hepatitis C virus in contrast to uninfected subjects. The elevation of D‐dimer levels supported the association between Chikungunya and the Zika virus and the rise of clinical VTE risk. Varicella‐zoster virus is a risk factor for both cellulitis and the consequent invasive bacterial disease which may take part in thrombotic initiation. Eventually, hospitalized patients infected with the coronavirus disease of 2019 (COVID‐19), the cause of the ongoing worldwide pandemic, could mainly suffer from an anomalous risk of coagulation activation with enhanced venous thrombosis events and poor quality clinical course. Although the risk of VTE in nonhospitalized COVID‐19 patients is not known yet, there are a large number of guidelines and studies on thromboprophylaxis administration for COVID‐19 cases. This study aims to take a detailed look at the effect of viral diseases on VTE, the epidemiology of VTE in viral diseases, and the diagnosis and treatment of VTE.

Cancer is one of the leading causes of mortality and morbidity worldwide, affecting millions of people physically and financially every year. Over time, many anticancer treatments have been proposed and studied, including synthetic compound consumption, surgical procedures, or grueling chemotherapy. Although these treatments have improved the daily life quality of patients and increased their survival rate and life expectancy, they have also shown significant drawbacks, including staggering costs, multiple side effects, and difficulty in compliance and adherence to treatment. Therefore, natural compounds have been considered a possible key to overcoming these problems in recent years, and thorough research has been done to assess their effectiveness. In these studies, scientists have discovered a meaningful interaction between several natural materials and signal transducer and activator of transcription 3 molecules. STAT3 is a transcriptional protein that is vital for cell growth and survival. Mechanistic studies have established that activated STAT3 can increase cancer cell proliferation and invasion while reducing anticancer immunity. Thus, inhibiting STAT3 signaling by natural compounds has become one of the favorite research topics and an attractive target for developing novel cancer treatments. In the present article, we intend to comprehensively review the latest knowledge about the effects of various organic compounds on inhibiting the STAT3 signaling pathway to cure different cancer diseases.

Background and Aim: In late 2021, the world faced the rapid spread of the SARS‐CoV‐2 Omicron variant, which quickly became the variant of concern. In April 2022, two new lineages of Omicron (BA.4/BA.5) emerged from Africa, where they caused the fifth wave of infection. Method: We searched PubMed, Google Scholar, and Scopus online databases up to December 2023 for founding relevant studies. Results: BA.4 and BA.5 subgroups, with changes in the spike protein, have a greater ability to escape from the immune system, which was possible with the help of L452R and F486V mutations. Epidemiologically, these evolving subtypes show similarities to seasonal influenza but with higher mortality rates. The symptoms of these subgroups are different from the previous types in the form of upper respiratory symptoms. Antiviral treatments, the use of antibodies such as bebtelovimab, and the development of vaccines are promising. Conclusion: Consequently, we must continue to be vigilant in our joint surveillance efforts against COVID‐19 in diagnosis and treatment.

Background and aims: Impaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition. A subset of non-small cell lung cancers (NSCLCs) harbour impaired DNA double strand break repair. This study aims to investigate meta-analysis on the olaparib monotherapy or combination therapy in lung cancer.Methods: A comprehensive search was conducted in Pubmed, Scopus and Google Scholar data bases up to August 13, 2023 related articles were extracted title, abstract and full text of articles were screened. The quality included articles were assessing the data was extracted and hence analysis.Results: After screening 5208 articles, 9 were selected for final review based on relevance to the topic. Olaparib monotherapy increased progression free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. Olaparib maintenance therapy increased PFS compared to placebo in platinum-sensitive NSCLC patients [ES= 0.9; 95% CI= 0.9 to 0.9]. Combination therapy with durvalumab and olaparib decreased PFS level compared to the olaparib group [ES=6.07; 95% confidence interval (95% CI) = 0.67 to 11.46; P=0.000]. Adding gefitinib to olaparib decreased PFS compared to olaparib only group, significantly (ES=3.39; 95% CI=-0.78 to 7.56; P=0.609).Conclusions: Our study demonstrated olaparib as monotherapy can increase the PFS of patients with lung cancer, but the combination of olaparib and gefitinib or the combination of olaparib plus durvalumab couldn’t have a significant effect. According to the high heterogeneous rate of studies further large-scale randomized control trials are still required to progress association.Systematic Review Registration: Open Science Framework (OSF).

Background: Congenital heart disease (CHD) affects 0.8%–1.2% of newborns globally, posing challenges to growth and nutrition. This cross-sectional study, conducted at Shahid Madani Hospital, Tabriz, aimed to assess growth patterns in 200 CHD patients (cyanotic and non-cyanotic) aged 1 month to 15 years before and after open-heart surgery.Methods: Data were collected from March 2016 to March 2020, including patient records, growth measurements, surgical details, and postoperative outcomes. Patients were categorized into cyanotic and non-cyanotic groups. Inclusion criteria involved CHD patients undergoing surgery with 1–2 years of follow-up. To compare growth disorders between cyanotic and non-cyanotic groups, logistic regression was used, adjusting for age and gender. The significance level was set at 0.05 for statistical analysis.Results: A total of 200 patients suffered from CHD underwent growth disorder examination in before and after surgery. The prevalence of weight growth disorder reduced from 44% in preoperative to 3.5% in 2 years after surgery. Similarly, the height and head circumference growth disorders experienced reduction from 40.5% and 6.5% to 9.5% and 1.5%, respectively. Generally, growth disorders were higher in cyanotic compared to non-cyanotic group. However, this difference was only significant in weight and height growth disorders in cyanotic vs. non-cyanotic groups after 1 year from surgery (p = 0.024, 0.038). The duration of PICU (8.11 ± 5.47 vs. 8.84 ± 5.83 days) and ward (4.40 ± 3.46 vs. 3.57 ± 2.20 days) hospitalization was longer for non-cyanotic vs. cyanotic groups, both suffering from growth disorders.Conclusion: Despite advancements in pediatric cardiac surgery, CHD children face growth challenges, especially in the cyanotic group. Timely surgical intervention demonstrated improvements, but growth disorders persisted in the long term, impacting PICU and inpatient ward stays. Targeted interventions are crucial to mitigate mortality risks associated with growth impairments in CHD children.

Herbal medicine has gained massive popularity among researchers worldwide. The leading causes of this rapid development are lower side effects, lower prices, and higher availability of plant extracts compared to synthetic drugs. Ginger (Zingiber officinale), from the Zingiberaceae family, is one of the most commonly used and popular plants utilized as a dietary spice, herbal medicine, and food preservative. Its biologically active components, such as shogaol, paradol, zingerone, and especially gingerol, can be highly effective for the treatment of several illnesses through various anti-inflammatory, anti-neoplastic, anti-emetic, anti-oxidant, antihyperlipidemic and anti-hyperglycaemic activities. Ginger can also be used as an antiviral agent. Numerous studies have been conducted to investigate the antiviral efficacy of ginger on several viruses; for instance, severe acute respiratory syndrome 2 (SARS-COV-2), influenza, dengue, hepatitis, herpes, Human Papilloma Virus (HPV), Human Immunodeficiency Virus (HIV), Epstein- Barr Virus (EBV), Chikungunya virus and so on. This review summarizes the efficacy of ginger in preventing or treating several viral diseases and its mechanism of action, emphasizing coronavirus disease 2019 (COVID-19) due to the current high burden of disease worldwide.